nodes	percent_of_prediction	percent_of_DWPC	metapath
Etodolac—RXRA—Isotretinoin—peripheral nervous system neoplasm	0.336	0.409	CbGbCtD
Etodolac—RXRA—Alitretinoin—peripheral nervous system neoplasm	0.207	0.253	CbGbCtD
Etodolac—RXRA—Tretinoin—peripheral nervous system neoplasm	0.193	0.235	CbGbCtD
Etodolac—UGT2B7—Epirubicin—peripheral nervous system neoplasm	0.0325	0.0396	CbGbCtD
Etodolac—PTGS2—Cisplatin—peripheral nervous system neoplasm	0.0134	0.0163	CbGbCtD
Etodolac—PTGS2—Etoposide—peripheral nervous system neoplasm	0.0132	0.016	CbGbCtD
Etodolac—PTGS1—Etoposide—peripheral nervous system neoplasm	0.0111	0.0135	CbGbCtD
Etodolac—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0106	0.0129	CbGbCtD
Etodolac—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.00455	0.00554	CbGbCtD
Etodolac—UGT1A10—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.000593	0.173	CbGpPWpGaD
Etodolac—UGT2B7—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.000237	0.0689	CbGpPWpGaD
Etodolac—UGT1A9—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.000163	0.0475	CbGpPWpGaD
Etodolac—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000103	0.000588	CcSEcCtD
Etodolac—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000103	0.000585	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000102	0.000582	CcSEcCtD
Etodolac—Infection—Etoposide—peripheral nervous system neoplasm	0.000102	0.000582	CcSEcCtD
Etodolac—Abdominal distension—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000581	CcSEcCtD
Etodolac—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000102	0.00058	CcSEcCtD
Etodolac—Nausea—Melphalan—peripheral nervous system neoplasm	0.000102	0.00058	CcSEcCtD
Etodolac—Asthma—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000577	CcSEcCtD
Etodolac—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000101	0.000574	CcSEcCtD
Etodolac—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000101	0.000573	CcSEcCtD
Etodolac—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.0001	0.000571	CcSEcCtD
Etodolac—Eosinophilia—Epirubicin—peripheral nervous system neoplasm	0.0001	0.000571	CcSEcCtD
Etodolac—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.0001	0.000571	CcSEcCtD
Etodolac—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.0001	0.000571	CcSEcCtD
Etodolac—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.0001	0.00057	CcSEcCtD
Etodolac—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	9.93e-05	0.000566	CcSEcCtD
Etodolac—Pancreatitis—Epirubicin—peripheral nervous system neoplasm	9.93e-05	0.000566	CcSEcCtD
Etodolac—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	9.9e-05	0.000564	CcSEcCtD
Etodolac—Anorexia—Etoposide—peripheral nervous system neoplasm	9.79e-05	0.000558	CcSEcCtD
Etodolac—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	9.76e-05	0.000556	CcSEcCtD
Etodolac—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	9.75e-05	0.000556	CcSEcCtD
Etodolac—Bronchitis—Epirubicin—peripheral nervous system neoplasm	9.74e-05	0.000555	CcSEcCtD
Etodolac—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	9.71e-05	0.000553	CcSEcCtD
Etodolac—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	9.7e-05	0.000553	CcSEcCtD
Etodolac—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	9.62e-05	0.000548	CcSEcCtD
Etodolac—Hypotension—Etoposide—peripheral nervous system neoplasm	9.6e-05	0.000547	CcSEcCtD
Etodolac—Gastritis—Doxorubicin—peripheral nervous system neoplasm	9.6e-05	0.000547	CcSEcCtD
Etodolac—Pain—Cisplatin—peripheral nervous system neoplasm	9.59e-05	0.000546	CcSEcCtD
Etodolac—Neutropenia—Epirubicin—peripheral nervous system neoplasm	9.47e-05	0.00054	CcSEcCtD
Etodolac—Dysuria—Epirubicin—peripheral nervous system neoplasm	9.47e-05	0.00054	CcSEcCtD
Etodolac—Asthenia—Alitretinoin—peripheral nervous system neoplasm	9.44e-05	0.000538	CcSEcCtD
Etodolac—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	9.43e-05	0.000538	CcSEcCtD
Etodolac—Asthma—Doxorubicin—peripheral nervous system neoplasm	9.37e-05	0.000534	CcSEcCtD
Etodolac—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	9.36e-05	0.000533	CcSEcCtD
Etodolac—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	9.35e-05	0.000532	CcSEcCtD
Etodolac—Pruritus—Alitretinoin—peripheral nervous system neoplasm	9.31e-05	0.000531	CcSEcCtD
Etodolac—Eosinophilia—Doxorubicin—peripheral nervous system neoplasm	9.28e-05	0.000529	CcSEcCtD
Etodolac—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	9.25e-05	0.000527	CcSEcCtD
Etodolac—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	9.24e-05	0.000527	CcSEcCtD
Etodolac—Paraesthesia—Etoposide—peripheral nervous system neoplasm	9.23e-05	0.000526	CcSEcCtD
Etodolac—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	9.19e-05	0.000524	CcSEcCtD
Etodolac—UGT1A3—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	9.18e-05	0.0267	CbGpPWpGaD
Etodolac—Dyspnoea—Etoposide—peripheral nervous system neoplasm	9.16e-05	0.000522	CcSEcCtD
Etodolac—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	9.14e-05	0.000521	CcSEcCtD
Etodolac—Somnolence—Etoposide—peripheral nervous system neoplasm	9.13e-05	0.00052	CcSEcCtD
Etodolac—Asthenia—Vincristine—peripheral nervous system neoplasm	9.1e-05	0.000519	CcSEcCtD
Etodolac—Pneumonia—Epirubicin—peripheral nervous system neoplasm	9.08e-05	0.000518	CcSEcCtD
Etodolac—Vomiting—Dactinomycin—peripheral nervous system neoplasm	9.03e-05	0.000514	CcSEcCtD
Etodolac—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	9.01e-05	0.000514	CcSEcCtD
Etodolac—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	9.01e-05	0.000513	CcSEcCtD
Etodolac—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	8.95e-05	0.00051	CcSEcCtD
Etodolac—Rash—Dactinomycin—peripheral nervous system neoplasm	8.95e-05	0.00051	CcSEcCtD
Etodolac—Decreased appetite—Etoposide—peripheral nervous system neoplasm	8.93e-05	0.000509	CcSEcCtD
Etodolac—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	8.9e-05	0.000507	CcSEcCtD
Etodolac—Renal failure—Epirubicin—peripheral nervous system neoplasm	8.88e-05	0.000506	CcSEcCtD
Etodolac—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	8.87e-05	0.000505	CcSEcCtD
Etodolac—Fatigue—Etoposide—peripheral nervous system neoplasm	8.86e-05	0.000505	CcSEcCtD
Etodolac—Stomatitis—Epirubicin—peripheral nervous system neoplasm	8.8e-05	0.000502	CcSEcCtD
Etodolac—Jaundice—Epirubicin—peripheral nervous system neoplasm	8.8e-05	0.000502	CcSEcCtD
Etodolac—Constipation—Etoposide—peripheral nervous system neoplasm	8.79e-05	0.000501	CcSEcCtD
Etodolac—Pain—Etoposide—peripheral nervous system neoplasm	8.79e-05	0.000501	CcSEcCtD
Etodolac—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	8.78e-05	0.0005	CcSEcCtD
Etodolac—Dysuria—Doxorubicin—peripheral nervous system neoplasm	8.76e-05	0.000499	CcSEcCtD
Etodolac—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	8.76e-05	0.000499	CcSEcCtD
Etodolac—Dizziness—Alitretinoin—peripheral nervous system neoplasm	8.7e-05	0.000496	CcSEcCtD
Etodolac—Diarrhoea—Vincristine—peripheral nervous system neoplasm	8.68e-05	0.000494	CcSEcCtD
Etodolac—Sweating—Epirubicin—peripheral nervous system neoplasm	8.66e-05	0.000493	CcSEcCtD
Etodolac—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	8.66e-05	0.000493	CcSEcCtD
Etodolac—Haematuria—Epirubicin—peripheral nervous system neoplasm	8.61e-05	0.000491	CcSEcCtD
Etodolac—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	8.55e-05	0.000487	CcSEcCtD
Etodolac—Sinusitis—Epirubicin—peripheral nervous system neoplasm	8.47e-05	0.000483	CcSEcCtD
Etodolac—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	8.47e-05	0.000482	CcSEcCtD
Etodolac—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	8.45e-05	0.000482	CcSEcCtD
Etodolac—Nausea—Dactinomycin—peripheral nervous system neoplasm	8.43e-05	0.00048	CcSEcCtD
Etodolac—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	8.43e-05	0.00048	CcSEcCtD
Etodolac—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	8.4e-05	0.000479	CcSEcCtD
Etodolac—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	8.4e-05	0.000479	CcSEcCtD
Etodolac—Dizziness—Vincristine—peripheral nervous system neoplasm	8.39e-05	0.000478	CcSEcCtD
Etodolac—Vomiting—Alitretinoin—peripheral nervous system neoplasm	8.37e-05	0.000477	CcSEcCtD
Etodolac—Rash—Alitretinoin—peripheral nervous system neoplasm	8.3e-05	0.000473	CcSEcCtD
Etodolac—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	8.29e-05	0.000472	CcSEcCtD
Etodolac—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	8.28e-05	0.000472	CcSEcCtD
Etodolac—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	8.26e-05	0.000471	CcSEcCtD
Etodolac—Headache—Alitretinoin—peripheral nervous system neoplasm	8.25e-05	0.00047	CcSEcCtD
Etodolac—Renal failure—Doxorubicin—peripheral nervous system neoplasm	8.21e-05	0.000468	CcSEcCtD
Etodolac—Urticaria—Etoposide—peripheral nervous system neoplasm	8.16e-05	0.000465	CcSEcCtD
Etodolac—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	8.15e-05	0.000464	CcSEcCtD
Etodolac—Jaundice—Doxorubicin—peripheral nervous system neoplasm	8.15e-05	0.000464	CcSEcCtD
Etodolac—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	8.15e-05	0.000464	CcSEcCtD
Etodolac—Rhinitis—Epirubicin—peripheral nervous system neoplasm	8.13e-05	0.000463	CcSEcCtD
Etodolac—Abdominal pain—Etoposide—peripheral nervous system neoplasm	8.12e-05	0.000463	CcSEcCtD
Etodolac—Body temperature increased—Etoposide—peripheral nervous system neoplasm	8.12e-05	0.000463	CcSEcCtD
Etodolac—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	8.12e-05	0.000463	CcSEcCtD
Etodolac—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	8.11e-05	0.000462	CcSEcCtD
Etodolac—Hepatitis—Epirubicin—peripheral nervous system neoplasm	8.11e-05	0.000462	CcSEcCtD
Etodolac—Vomiting—Vincristine—peripheral nervous system neoplasm	8.07e-05	0.00046	CcSEcCtD
Etodolac—Asthenia—Cisplatin—peripheral nervous system neoplasm	8.05e-05	0.000458	CcSEcCtD
Etodolac—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	8.05e-05	0.000458	CcSEcCtD
Etodolac—Sweating—Doxorubicin—peripheral nervous system neoplasm	8.01e-05	0.000456	CcSEcCtD
Etodolac—Rash—Vincristine—peripheral nervous system neoplasm	8e-05	0.000456	CcSEcCtD
Etodolac—Dermatitis—Vincristine—peripheral nervous system neoplasm	7.99e-05	0.000455	CcSEcCtD
Etodolac—Haematuria—Doxorubicin—peripheral nervous system neoplasm	7.97e-05	0.000454	CcSEcCtD
Etodolac—Headache—Vincristine—peripheral nervous system neoplasm	7.95e-05	0.000453	CcSEcCtD
Etodolac—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	7.84e-05	0.000447	CcSEcCtD
Etodolac—Nausea—Alitretinoin—peripheral nervous system neoplasm	7.82e-05	0.000445	CcSEcCtD
Etodolac—Visual impairment—Epirubicin—peripheral nervous system neoplasm	7.81e-05	0.000445	CcSEcCtD
Etodolac—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	7.8e-05	0.000444	CcSEcCtD
Etodolac—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	7.67e-05	0.000437	CcSEcCtD
Etodolac—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	7.67e-05	0.000437	CcSEcCtD
Etodolac—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	7.57e-05	0.000431	CcSEcCtD
Etodolac—Tinnitus—Epirubicin—peripheral nervous system neoplasm	7.56e-05	0.000431	CcSEcCtD
Etodolac—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	7.54e-05	0.00043	CcSEcCtD
Etodolac—Nausea—Vincristine—peripheral nervous system neoplasm	7.53e-05	0.000429	CcSEcCtD
Etodolac—Flushing—Epirubicin—peripheral nervous system neoplasm	7.52e-05	0.000429	CcSEcCtD
Etodolac—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	7.52e-05	0.000428	CcSEcCtD
Etodolac—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	7.5e-05	0.000427	CcSEcCtD
Etodolac—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	7.5e-05	0.000427	CcSEcCtD
Etodolac—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	7.45e-05	0.000424	CcSEcCtD
Etodolac—Asthenia—Etoposide—peripheral nervous system neoplasm	7.37e-05	0.00042	CcSEcCtD
Etodolac—RXRA—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	7.28e-05	0.0212	CbGpPWpGaD
Etodolac—Chills—Epirubicin—peripheral nervous system neoplasm	7.27e-05	0.000414	CcSEcCtD
Etodolac—Pruritus—Etoposide—peripheral nervous system neoplasm	7.27e-05	0.000414	CcSEcCtD
Etodolac—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	7.24e-05	0.000413	CcSEcCtD
Etodolac—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	7.23e-05	0.000412	CcSEcCtD
Etodolac—Alopecia—Epirubicin—peripheral nervous system neoplasm	7.16e-05	0.000408	CcSEcCtD
Etodolac—Vomiting—Cisplatin—peripheral nervous system neoplasm	7.13e-05	0.000406	CcSEcCtD
Etodolac—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	7.09e-05	0.000404	CcSEcCtD
Etodolac—Rash—Cisplatin—peripheral nervous system neoplasm	7.07e-05	0.000403	CcSEcCtD
Etodolac—Dermatitis—Cisplatin—peripheral nervous system neoplasm	7.07e-05	0.000403	CcSEcCtD
Etodolac—Diarrhoea—Etoposide—peripheral nervous system neoplasm	7.03e-05	0.000401	CcSEcCtD
Etodolac—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	6.99e-05	0.000398	CcSEcCtD
Etodolac—Flushing—Doxorubicin—peripheral nervous system neoplasm	6.96e-05	0.000397	CcSEcCtD
Etodolac—Flatulence—Epirubicin—peripheral nervous system neoplasm	6.95e-05	0.000396	CcSEcCtD
Etodolac—Tension—Epirubicin—peripheral nervous system neoplasm	6.93e-05	0.000395	CcSEcCtD
Etodolac—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	6.91e-05	0.000394	CcSEcCtD
Etodolac—Nervousness—Epirubicin—peripheral nervous system neoplasm	6.85e-05	0.000391	CcSEcCtD
Etodolac—Dizziness—Etoposide—peripheral nervous system neoplasm	6.79e-05	0.000387	CcSEcCtD
Etodolac—RXRA—Orphan transporters—COX2—peripheral nervous system neoplasm	6.79e-05	0.0198	CbGpPWpGaD
Etodolac—Chills—Doxorubicin—peripheral nervous system neoplasm	6.73e-05	0.000383	CcSEcCtD
Etodolac—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	6.7e-05	0.000382	CcSEcCtD
Etodolac—Nausea—Cisplatin—peripheral nervous system neoplasm	6.66e-05	0.00038	CcSEcCtD
Etodolac—Vision blurred—Epirubicin—peripheral nervous system neoplasm	6.65e-05	0.000379	CcSEcCtD
Etodolac—Alopecia—Doxorubicin—peripheral nervous system neoplasm	6.63e-05	0.000378	CcSEcCtD
Etodolac—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—HSD17B12—peripheral nervous system neoplasm	6.56e-05	0.0191	CbGpPWpGaD
Etodolac—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	6.55e-05	0.000373	CcSEcCtD
Etodolac—Vomiting—Etoposide—peripheral nervous system neoplasm	6.53e-05	0.000372	CcSEcCtD
Etodolac—Anaemia—Epirubicin—peripheral nervous system neoplasm	6.52e-05	0.000372	CcSEcCtD
Etodolac—Rash—Etoposide—peripheral nervous system neoplasm	6.48e-05	0.000369	CcSEcCtD
Etodolac—Dermatitis—Etoposide—peripheral nervous system neoplasm	6.47e-05	0.000369	CcSEcCtD
Etodolac—Headache—Etoposide—peripheral nervous system neoplasm	6.44e-05	0.000367	CcSEcCtD
Etodolac—Flatulence—Doxorubicin—peripheral nervous system neoplasm	6.43e-05	0.000367	CcSEcCtD
Etodolac—Tension—Doxorubicin—peripheral nervous system neoplasm	6.41e-05	0.000365	CcSEcCtD
Etodolac—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	6.39e-05	0.000364	CcSEcCtD
Etodolac—Malaise—Epirubicin—peripheral nervous system neoplasm	6.36e-05	0.000363	CcSEcCtD
Etodolac—Nervousness—Doxorubicin—peripheral nervous system neoplasm	6.34e-05	0.000361	CcSEcCtD
Etodolac—UGT1A9—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	6.34e-05	0.0185	CbGpPWpGaD
Etodolac—Vertigo—Epirubicin—peripheral nervous system neoplasm	6.34e-05	0.000361	CcSEcCtD
Etodolac—Syncope—Epirubicin—peripheral nervous system neoplasm	6.33e-05	0.000361	CcSEcCtD
Etodolac—Leukopenia—Epirubicin—peripheral nervous system neoplasm	6.32e-05	0.00036	CcSEcCtD
Etodolac—Palpitations—Epirubicin—peripheral nervous system neoplasm	6.24e-05	0.000355	CcSEcCtD
Etodolac—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	6.2e-05	0.000353	CcSEcCtD
Etodolac—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	6.15e-05	0.000351	CcSEcCtD
Etodolac—Convulsion—Epirubicin—peripheral nervous system neoplasm	6.11e-05	0.000348	CcSEcCtD
Etodolac—Nausea—Etoposide—peripheral nervous system neoplasm	6.1e-05	0.000348	CcSEcCtD
Etodolac—Hypertension—Epirubicin—peripheral nervous system neoplasm	6.09e-05	0.000347	CcSEcCtD
Etodolac—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	6.06e-05	0.000345	CcSEcCtD
Etodolac—Anaemia—Doxorubicin—peripheral nervous system neoplasm	6.04e-05	0.000344	CcSEcCtD
Etodolac—Arthralgia—Epirubicin—peripheral nervous system neoplasm	6.01e-05	0.000342	CcSEcCtD
Etodolac—Myalgia—Epirubicin—peripheral nervous system neoplasm	6.01e-05	0.000342	CcSEcCtD
Etodolac—Anxiety—Epirubicin—peripheral nervous system neoplasm	5.99e-05	0.000341	CcSEcCtD
Etodolac—Discomfort—Epirubicin—peripheral nervous system neoplasm	5.94e-05	0.000338	CcSEcCtD
Etodolac—Malaise—Doxorubicin—peripheral nervous system neoplasm	5.89e-05	0.000336	CcSEcCtD
Etodolac—Dry mouth—Epirubicin—peripheral nervous system neoplasm	5.88e-05	0.000335	CcSEcCtD
Etodolac—Vertigo—Doxorubicin—peripheral nervous system neoplasm	5.87e-05	0.000334	CcSEcCtD
Etodolac—Syncope—Doxorubicin—peripheral nervous system neoplasm	5.86e-05	0.000334	CcSEcCtD
Etodolac—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	5.85e-05	0.000333	CcSEcCtD
Etodolac—Confusional state—Epirubicin—peripheral nervous system neoplasm	5.81e-05	0.000331	CcSEcCtD
Etodolac—PTGS2—Aryl Hydrocarbon Receptor—NF1—peripheral nervous system neoplasm	5.79e-05	0.0168	CbGpPWpGaD
Etodolac—Palpitations—Doxorubicin—peripheral nervous system neoplasm	5.77e-05	0.000329	CcSEcCtD
Etodolac—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	5.76e-05	0.000328	CcSEcCtD
Etodolac—Oedema—Epirubicin—peripheral nervous system neoplasm	5.76e-05	0.000328	CcSEcCtD
Etodolac—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	5.74e-05	0.000327	CcSEcCtD
Etodolac—Infection—Epirubicin—peripheral nervous system neoplasm	5.72e-05	0.000326	CcSEcCtD
Etodolac—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—HSD17B12—peripheral nervous system neoplasm	5.71e-05	0.0166	CbGpPWpGaD
Etodolac—Shock—Epirubicin—peripheral nervous system neoplasm	5.67e-05	0.000323	CcSEcCtD
Etodolac—Convulsion—Doxorubicin—peripheral nervous system neoplasm	5.66e-05	0.000322	CcSEcCtD
Etodolac—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	5.64e-05	0.000321	CcSEcCtD
Etodolac—Hypertension—Doxorubicin—peripheral nervous system neoplasm	5.64e-05	0.000321	CcSEcCtD
Etodolac—Tachycardia—Epirubicin—peripheral nervous system neoplasm	5.62e-05	0.00032	CcSEcCtD
Etodolac—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	5.57e-05	0.000317	CcSEcCtD
Etodolac—Myalgia—Doxorubicin—peripheral nervous system neoplasm	5.56e-05	0.000317	CcSEcCtD
Etodolac—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	5.56e-05	0.000317	CcSEcCtD
Etodolac—Anxiety—Doxorubicin—peripheral nervous system neoplasm	5.54e-05	0.000316	CcSEcCtD
Etodolac—Discomfort—Doxorubicin—peripheral nervous system neoplasm	5.49e-05	0.000313	CcSEcCtD
Etodolac—Anorexia—Epirubicin—peripheral nervous system neoplasm	5.49e-05	0.000313	CcSEcCtD
Etodolac—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	5.44e-05	0.00031	CcSEcCtD
Etodolac—Hypotension—Epirubicin—peripheral nervous system neoplasm	5.38e-05	0.000307	CcSEcCtD
Etodolac—Confusional state—Doxorubicin—peripheral nervous system neoplasm	5.37e-05	0.000306	CcSEcCtD
Etodolac—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	5.33e-05	0.000304	CcSEcCtD
Etodolac—Oedema—Doxorubicin—peripheral nervous system neoplasm	5.33e-05	0.000304	CcSEcCtD
Etodolac—Infection—Doxorubicin—peripheral nervous system neoplasm	5.29e-05	0.000302	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	5.25e-05	0.000299	CcSEcCtD
Etodolac—Shock—Doxorubicin—peripheral nervous system neoplasm	5.24e-05	0.000299	CcSEcCtD
Etodolac—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	5.22e-05	0.000297	CcSEcCtD
Etodolac—Insomnia—Epirubicin—peripheral nervous system neoplasm	5.21e-05	0.000297	CcSEcCtD
Etodolac—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	5.2e-05	0.000296	CcSEcCtD
Etodolac—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	5.17e-05	0.000295	CcSEcCtD
Etodolac—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	5.15e-05	0.000294	CcSEcCtD
Etodolac—RXRA—The citric acid (TCA) cycle and respiratory electron transport—COX2—peripheral nervous system neoplasm	5.15e-05	0.015	CbGpPWpGaD
Etodolac—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	5.14e-05	0.000293	CcSEcCtD
Etodolac—Somnolence—Epirubicin—peripheral nervous system neoplasm	5.12e-05	0.000292	CcSEcCtD
Etodolac—Anorexia—Doxorubicin—peripheral nervous system neoplasm	5.08e-05	0.000289	CcSEcCtD
Etodolac—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	5.07e-05	0.000289	CcSEcCtD
Etodolac—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	5.01e-05	0.000285	CcSEcCtD
Etodolac—Hypotension—Doxorubicin—peripheral nervous system neoplasm	4.98e-05	0.000284	CcSEcCtD
Etodolac—Fatigue—Epirubicin—peripheral nervous system neoplasm	4.97e-05	0.000283	CcSEcCtD
Etodolac—Pain—Epirubicin—peripheral nervous system neoplasm	4.93e-05	0.000281	CcSEcCtD
Etodolac—Constipation—Epirubicin—peripheral nervous system neoplasm	4.93e-05	0.000281	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	4.86e-05	0.000277	CcSEcCtD
Etodolac—ALB—FOXA2 and FOXA3 transcription factor networks—NF1—peripheral nervous system neoplasm	4.85e-05	0.0141	CbGpPWpGaD
Etodolac—Insomnia—Doxorubicin—peripheral nervous system neoplasm	4.82e-05	0.000275	CcSEcCtD
Etodolac—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	4.79e-05	0.000273	CcSEcCtD
Etodolac—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	4.75e-05	0.000271	CcSEcCtD
Etodolac—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	4.75e-05	0.00027	CcSEcCtD
Etodolac—Somnolence—Doxorubicin—peripheral nervous system neoplasm	4.74e-05	0.00027	CcSEcCtD
Etodolac—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	4.71e-05	0.000268	CcSEcCtD
Etodolac—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	4.69e-05	0.000267	CcSEcCtD
Etodolac—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	4.63e-05	0.000264	CcSEcCtD
Etodolac—Fatigue—Doxorubicin—peripheral nervous system neoplasm	4.59e-05	0.000262	CcSEcCtD
Etodolac—Urticaria—Epirubicin—peripheral nervous system neoplasm	4.58e-05	0.000261	CcSEcCtD
Etodolac—Constipation—Doxorubicin—peripheral nervous system neoplasm	4.56e-05	0.00026	CcSEcCtD
Etodolac—Pain—Doxorubicin—peripheral nervous system neoplasm	4.56e-05	0.00026	CcSEcCtD
Etodolac—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	4.55e-05	0.000259	CcSEcCtD
Etodolac—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	4.55e-05	0.000259	CcSEcCtD
Etodolac—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	4.39e-05	0.00025	CcSEcCtD
Etodolac—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	4.36e-05	0.000248	CcSEcCtD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	4.34e-05	0.0126	CbGpPWpGaD
Etodolac—RXRA—a6b1 and a6b4 Integrin signaling—MET—peripheral nervous system neoplasm	4.24e-05	0.0124	CbGpPWpGaD
Etodolac—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	4.24e-05	0.000242	CcSEcCtD
Etodolac—Urticaria—Doxorubicin—peripheral nervous system neoplasm	4.23e-05	0.000241	CcSEcCtD
Etodolac—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	4.21e-05	0.00024	CcSEcCtD
Etodolac—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	4.21e-05	0.00024	CcSEcCtD
Etodolac—Asthenia—Epirubicin—peripheral nervous system neoplasm	4.13e-05	0.000235	CcSEcCtD
Etodolac—Pruritus—Epirubicin—peripheral nervous system neoplasm	4.08e-05	0.000232	CcSEcCtD
Etodolac—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	3.94e-05	0.000225	CcSEcCtD
Etodolac—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	3.93e-05	0.000224	CcSEcCtD
Etodolac—Asthenia—Doxorubicin—peripheral nervous system neoplasm	3.82e-05	0.000218	CcSEcCtD
Etodolac—Dizziness—Epirubicin—peripheral nervous system neoplasm	3.81e-05	0.000217	CcSEcCtD
Etodolac—Pruritus—Doxorubicin—peripheral nervous system neoplasm	3.77e-05	0.000215	CcSEcCtD
Etodolac—Vomiting—Epirubicin—peripheral nervous system neoplasm	3.66e-05	0.000209	CcSEcCtD
Etodolac—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	3.65e-05	0.000208	CcSEcCtD
Etodolac—Rash—Epirubicin—peripheral nervous system neoplasm	3.63e-05	0.000207	CcSEcCtD
Etodolac—Dermatitis—Epirubicin—peripheral nervous system neoplasm	3.63e-05	0.000207	CcSEcCtD
Etodolac—Headache—Epirubicin—peripheral nervous system neoplasm	3.61e-05	0.000206	CcSEcCtD
Etodolac—PTGS2—C-MYB transcription factor network—CD34—peripheral nervous system neoplasm	3.57e-05	0.0104	CbGpPWpGaD
Etodolac—Dizziness—Doxorubicin—peripheral nervous system neoplasm	3.52e-05	0.000201	CcSEcCtD
Etodolac—UGT1A3—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	3.45e-05	0.0101	CbGpPWpGaD
Etodolac—Nausea—Epirubicin—peripheral nervous system neoplasm	3.42e-05	0.000195	CcSEcCtD
Etodolac—RXRA—PPAR Alpha Pathway—MYC—peripheral nervous system neoplasm	3.41e-05	0.00993	CbGpPWpGaD
Etodolac—Vomiting—Doxorubicin—peripheral nervous system neoplasm	3.39e-05	0.000193	CcSEcCtD
Etodolac—Rash—Doxorubicin—peripheral nervous system neoplasm	3.36e-05	0.000191	CcSEcCtD
Etodolac—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	3.36e-05	0.000191	CcSEcCtD
Etodolac—Headache—Doxorubicin—peripheral nervous system neoplasm	3.34e-05	0.00019	CcSEcCtD
Etodolac—Nausea—Doxorubicin—peripheral nervous system neoplasm	3.17e-05	0.00018	CcSEcCtD
Etodolac—RXRA—a6b1 and a6b4 Integrin signaling—ERBB2—peripheral nervous system neoplasm	3.1e-05	0.00903	CbGpPWpGaD
Etodolac—UGT1A9—PPAR Alpha Pathway—MYC—peripheral nervous system neoplasm	2.97e-05	0.00865	CbGpPWpGaD
Etodolac—UGT2B7—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	2.94e-05	0.00855	CbGpPWpGaD
Etodolac—RXRA—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	2.74e-05	0.00797	CbGpPWpGaD
Etodolac—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	2.72e-05	0.00791	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—CNTN6—peripheral nervous system neoplasm	2.67e-05	0.00779	CbGpPWpGaD
Etodolac—UGT1A3—NRF2 pathway—HGF—peripheral nervous system neoplasm	2.65e-05	0.0077	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	2.61e-05	0.00761	CbGpPWpGaD
Etodolac—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	2.59e-05	0.00754	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	2.44e-05	0.00712	CbGpPWpGaD
Etodolac—UGT1A9—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	2.39e-05	0.00695	CbGpPWpGaD
Etodolac—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC2A1—peripheral nervous system neoplasm	2.34e-05	0.0068	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	2.28e-05	0.00663	CbGpPWpGaD
Etodolac—UGT2B7—NRF2 pathway—HGF—peripheral nervous system neoplasm	2.25e-05	0.00655	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.17e-05	0.00632	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	2.12e-05	0.00619	CbGpPWpGaD
Etodolac—RXRA—Retinoic acid receptors-mediated signaling—AKT1—peripheral nervous system neoplasm	2.11e-05	0.00614	CbGpPWpGaD
Etodolac—RXRA—NRF2 pathway—HGF—peripheral nervous system neoplasm	2.1e-05	0.00611	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	1.94e-05	0.00564	CbGpPWpGaD
Etodolac—ALB—Platelet degranulation—KNG1—peripheral nervous system neoplasm	1.86e-05	0.00541	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	1.85e-05	0.0054	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.85e-05	0.00538	CbGpPWpGaD
Etodolac—UGT1A9—NRF2 pathway—HGF—peripheral nervous system neoplasm	1.83e-05	0.00532	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	1.77e-05	0.00516	CbGpPWpGaD
Etodolac—ALB—Response to elevated platelet cytosolic Ca2+—KNG1—peripheral nervous system neoplasm	1.77e-05	0.00516	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	1.74e-05	0.00508	CbGpPWpGaD
Etodolac—RXRA—a6b1 and a6b4 Integrin signaling—HRAS—peripheral nervous system neoplasm	1.73e-05	0.00503	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.72e-05	0.00501	CbGpPWpGaD
Etodolac—RXRA—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	1.66e-05	0.00482	CbGpPWpGaD
Etodolac—ALB—Platelet degranulation—HGF—peripheral nervous system neoplasm	1.55e-05	0.00451	CbGpPWpGaD
Etodolac—RXRA—a6b1 and a6b4 Integrin signaling—AKT1—peripheral nervous system neoplasm	1.52e-05	0.00444	CbGpPWpGaD
Etodolac—SLC22A6—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	1.51e-05	0.00441	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.5e-05	0.00437	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—EED—peripheral nervous system neoplasm	1.5e-05	0.00436	CbGpPWpGaD
Etodolac—ALB—Response to elevated platelet cytosolic Ca2+—HGF—peripheral nervous system neoplasm	1.48e-05	0.0043	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	1.47e-05	0.00429	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—BDNF—peripheral nervous system neoplasm	1.47e-05	0.00428	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.47e-05	0.00427	CbGpPWpGaD
Etodolac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—peripheral nervous system neoplasm	1.46e-05	0.00425	CbGpPWpGaD
Etodolac—SLC22A6—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	1.45e-05	0.00423	CbGpPWpGaD
Etodolac—PTGS2—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	1.31e-05	0.00381	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—NCAM1—peripheral nervous system neoplasm	1.31e-05	0.0038	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.25e-05	0.00363	CbGpPWpGaD
Etodolac—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—peripheral nervous system neoplasm	1.24e-05	0.00362	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.22e-05	0.00356	CbGpPWpGaD
Etodolac—PTGS2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	1.22e-05	0.00355	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	1.2e-05	0.00349	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—SUZ12—peripheral nervous system neoplasm	1.2e-05	0.00348	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	1.19e-05	0.00347	CbGpPWpGaD
Etodolac—RXRA—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.16e-05	0.00339	CbGpPWpGaD
Etodolac—PTGS2—C-MYB transcription factor network—CDKN2A—peripheral nervous system neoplasm	1.11e-05	0.00323	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	1.09e-05	0.00318	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—GNS—peripheral nervous system neoplasm	1.06e-05	0.00309	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—NME1—peripheral nervous system neoplasm	1.02e-05	0.00296	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.01e-05	0.00295	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	1e-05	0.00291	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	9.83e-06	0.00286	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—COX2—peripheral nervous system neoplasm	9.78e-06	0.00285	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	9.76e-06	0.00284	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	9.75e-06	0.00284	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	9.71e-06	0.00283	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	9.67e-06	0.00281	CbGpPWpGaD
Etodolac—PTGS2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	9.56e-06	0.00278	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—GNS—peripheral nervous system neoplasm	9.02e-06	0.00263	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	8.86e-06	0.00258	CbGpPWpGaD
Etodolac—RXRA—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	8.77e-06	0.00255	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—NME1—peripheral nervous system neoplasm	8.64e-06	0.00252	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	8.42e-06	0.00245	CbGpPWpGaD
Etodolac—RXRA—Metabolism—GNS—peripheral nervous system neoplasm	8.41e-06	0.00245	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—COX2—peripheral nervous system neoplasm	8.32e-06	0.00242	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—HSD17B12—peripheral nervous system neoplasm	8.26e-06	0.00241	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—KNG1—peripheral nervous system neoplasm	8.25e-06	0.0024	CbGpPWpGaD
Etodolac—PTGS2—C-MYB transcription factor network—NRAS—peripheral nervous system neoplasm	8.08e-06	0.00235	CbGpPWpGaD
Etodolac—RXRA—Metabolism—NME1—peripheral nervous system neoplasm	8.06e-06	0.00235	CbGpPWpGaD
Etodolac—ALB—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	7.87e-06	0.00229	CbGpPWpGaD
Etodolac—ALB—Metabolism—PPIP5K2—peripheral nervous system neoplasm	7.85e-06	0.00229	CbGpPWpGaD
Etodolac—RXRA—Metabolism—COX2—peripheral nervous system neoplasm	7.76e-06	0.00226	CbGpPWpGaD
Etodolac—SLC22A6—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	7.69e-06	0.00224	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	7.56e-06	0.0022	CbGpPWpGaD
Etodolac—PTGS2—C-MYB transcription factor network—MYC—peripheral nervous system neoplasm	7.52e-06	0.00219	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—CASP3—peripheral nervous system neoplasm	7.34e-06	0.00214	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—GNS—peripheral nervous system neoplasm	7.33e-06	0.00213	CbGpPWpGaD
Etodolac—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—peripheral nervous system neoplasm	7.08e-06	0.00206	CbGpPWpGaD
Etodolac—RXRA—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	7.05e-06	0.00205	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—NME1—peripheral nervous system neoplasm	7.02e-06	0.00205	CbGpPWpGaD
Etodolac—RXRA—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	6.92e-06	0.00202	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	6.92e-06	0.00201	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—HGF—peripheral nervous system neoplasm	6.87e-06	0.002	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	6.86e-06	0.002	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—COX2—peripheral nervous system neoplasm	6.76e-06	0.00197	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—HSD17B12—peripheral nervous system neoplasm	6.56e-06	0.00191	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	6.43e-06	0.00187	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—ENO2—peripheral nervous system neoplasm	6.42e-06	0.00187	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—MET—peripheral nervous system neoplasm	6.24e-06	0.00182	CbGpPWpGaD
Etodolac—SLC22A6—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	6.19e-06	0.0018	CbGpPWpGaD
Etodolac—SLC22A6—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	6.07e-06	0.00177	CbGpPWpGaD
Etodolac—ALB—Folate Metabolism—TP53—peripheral nervous system neoplasm	6.06e-06	0.00176	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—GNS—peripheral nervous system neoplasm	5.97e-06	0.00174	CbGpPWpGaD
Etodolac—PTGS2—C-MYB transcription factor network—HRAS—peripheral nervous system neoplasm	5.91e-06	0.00172	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—PTPN11—peripheral nervous system neoplasm	5.77e-06	0.00168	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—MYC—peripheral nervous system neoplasm	5.73e-06	0.00167	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—NME1—peripheral nervous system neoplasm	5.73e-06	0.00167	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	5.68e-06	0.00165	CbGpPWpGaD
Etodolac—PTGS2—Disease—GNS—peripheral nervous system neoplasm	5.66e-06	0.00165	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—COX2—peripheral nervous system neoplasm	5.51e-06	0.0016	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	5.5e-06	0.0016	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—ENO2—peripheral nervous system neoplasm	5.46e-06	0.00159	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	5.45e-06	0.00159	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—BCHE—peripheral nervous system neoplasm	5.43e-06	0.00158	CbGpPWpGaD
Etodolac—ALB—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.31e-06	0.00154	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.18e-06	0.00151	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—TH—peripheral nervous system neoplasm	5.1e-06	0.00149	CbGpPWpGaD
Etodolac—RXRA—Metabolism—ENO2—peripheral nervous system neoplasm	5.09e-06	0.00148	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	4.99e-06	0.00145	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	4.8e-06	0.0014	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—GNS—peripheral nervous system neoplasm	4.74e-06	0.00138	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—TP53—peripheral nervous system neoplasm	4.71e-06	0.00137	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—BCHE—peripheral nervous system neoplasm	4.62e-06	0.00134	CbGpPWpGaD
Etodolac—ALB—Hemostasis—IFNB1—peripheral nervous system neoplasm	4.59e-06	0.00134	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—ERBB2—peripheral nervous system neoplasm	4.56e-06	0.00133	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—NME1—peripheral nervous system neoplasm	4.55e-06	0.00132	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—ENO2—peripheral nervous system neoplasm	4.44e-06	0.00129	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	4.41e-06	0.00128	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.4e-06	0.00128	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—COX2—peripheral nervous system neoplasm	4.38e-06	0.00127	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.34e-06	0.00126	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—TH—peripheral nervous system neoplasm	4.34e-06	0.00126	CbGpPWpGaD
Etodolac—RXRA—Metabolism—BCHE—peripheral nervous system neoplasm	4.3e-06	0.00125	CbGpPWpGaD
Etodolac—ALB—Hemostasis—KNG1—peripheral nervous system neoplasm	4.25e-06	0.00124	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—GNAS—peripheral nervous system neoplasm	4.17e-06	0.00121	CbGpPWpGaD
Etodolac—RXRA—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.11e-06	0.0012	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—ABCB1—peripheral nervous system neoplasm	4.09e-06	0.00119	CbGpPWpGaD
Etodolac—RXRA—Metabolism—TH—peripheral nervous system neoplasm	4.05e-06	0.00118	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	4e-06	0.00116	CbGpPWpGaD
Etodolac—PTGS2—Disease—PPP3R1—peripheral nervous system neoplasm	3.96e-06	0.00115	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	3.9e-06	0.00114	CbGpPWpGaD
Etodolac—ALB—Metabolism—GNS—peripheral nervous system neoplasm	3.84e-06	0.00112	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—BCHE—peripheral nervous system neoplasm	3.75e-06	0.00109	CbGpPWpGaD
Etodolac—ALB—Hemostasis—GNAS—peripheral nervous system neoplasm	3.72e-06	0.00108	CbGpPWpGaD
Etodolac—ALB—Metabolism—NME1—peripheral nervous system neoplasm	3.68e-06	0.00107	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—ENO2—peripheral nervous system neoplasm	3.62e-06	0.00105	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	3.61e-06	0.00105	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.58e-06	0.00104	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—GNAS—peripheral nervous system neoplasm	3.54e-06	0.00103	CbGpPWpGaD
Etodolac—ALB—Hemostasis—HGF—peripheral nervous system neoplasm	3.54e-06	0.00103	CbGpPWpGaD
Etodolac—ALB—Metabolism—COX2—peripheral nervous system neoplasm	3.54e-06	0.00103	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—TH—peripheral nervous system neoplasm	3.53e-06	0.00103	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—ABCB1—peripheral nervous system neoplasm	3.48e-06	0.00101	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—NRAS—peripheral nervous system neoplasm	3.47e-06	0.00101	CbGpPWpGaD
Etodolac—RXRA—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	3.44e-06	0.001	CbGpPWpGaD
Etodolac—PTGS2—Disease—ENO2—peripheral nervous system neoplasm	3.43e-06	0.000999	CbGpPWpGaD
Etodolac—RXRA—Metabolism—GNAS—peripheral nervous system neoplasm	3.3e-06	0.000962	CbGpPWpGaD
Etodolac—RXRA—Metabolism—ABCB1—peripheral nervous system neoplasm	3.24e-06	0.000944	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	3.22e-06	0.000937	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	3.2e-06	0.000932	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	3.16e-06	0.000919	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	3.14e-06	0.000914	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—BCHE—peripheral nervous system neoplasm	3.06e-06	0.00089	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	3.01e-06	0.000876	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.92e-06	0.000849	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	2.9e-06	0.000844	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—GNAS—peripheral nervous system neoplasm	2.88e-06	0.000838	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—TH—peripheral nervous system neoplasm	2.87e-06	0.000837	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—ENO2—peripheral nervous system neoplasm	2.87e-06	0.000836	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—ABCB1—peripheral nervous system neoplasm	2.82e-06	0.000822	CbGpPWpGaD
Etodolac—PTGS2—Disease—SLC2A1—peripheral nervous system neoplasm	2.76e-06	0.000805	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	2.7e-06	0.000787	CbGpPWpGaD
Etodolac—ALB—Hemostasis—PTPN11—peripheral nervous system neoplasm	2.58e-06	0.000752	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—HRAS—peripheral nervous system neoplasm	2.54e-06	0.00074	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—BCHE—peripheral nervous system neoplasm	2.43e-06	0.000707	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—GNAS—peripheral nervous system neoplasm	2.35e-06	0.000683	CbGpPWpGaD
Etodolac—ALB—Metabolism—ENO2—peripheral nervous system neoplasm	2.32e-06	0.000677	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.32e-06	0.000674	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—ABCB1—peripheral nervous system neoplasm	2.3e-06	0.00067	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—TH—peripheral nervous system neoplasm	2.28e-06	0.000664	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—AKT1—peripheral nervous system neoplasm	2.24e-06	0.000653	CbGpPWpGaD
Etodolac—ALB—Metabolism—BCHE—peripheral nervous system neoplasm	1.96e-06	0.000572	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	1.95e-06	0.000567	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	1.9e-06	0.000554	CbGpPWpGaD
Etodolac—ALB—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.87e-06	0.000545	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—GNAS—peripheral nervous system neoplasm	1.86e-06	0.000542	CbGpPWpGaD
Etodolac—ALB—Metabolism—TH—peripheral nervous system neoplasm	1.85e-06	0.000538	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—ABCB1—peripheral nervous system neoplasm	1.83e-06	0.000532	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—MYC—peripheral nervous system neoplasm	1.65e-06	0.000482	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	1.61e-06	0.000468	CbGpPWpGaD
Etodolac—ALB—Hemostasis—NRAS—peripheral nervous system neoplasm	1.55e-06	0.000452	CbGpPWpGaD
Etodolac—PTGS2—Disease—PTPN11—peripheral nervous system neoplasm	1.55e-06	0.00045	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.53e-06	0.000446	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	1.51e-06	0.00044	CbGpPWpGaD
Etodolac—ALB—Metabolism—GNAS—peripheral nervous system neoplasm	1.51e-06	0.000439	CbGpPWpGaD
Etodolac—ALB—Metabolism—ABCB1—peripheral nervous system neoplasm	1.48e-06	0.000431	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	1.23e-06	0.000359	CbGpPWpGaD
Etodolac—PTGS2—Disease—ERBB2—peripheral nervous system neoplasm	1.22e-06	0.000356	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	1.21e-06	0.000352	CbGpPWpGaD
Etodolac—ALB—Hemostasis—TP53—peripheral nervous system neoplasm	1.19e-06	0.000346	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—AKT1—peripheral nervous system neoplasm	1.15e-06	0.000334	CbGpPWpGaD
Etodolac—ALB—Hemostasis—HRAS—peripheral nervous system neoplasm	1.14e-06	0.000331	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—AKT1—peripheral nervous system neoplasm	1.12e-06	0.000327	CbGpPWpGaD
Etodolac—ALB—Hemostasis—AKT1—peripheral nervous system neoplasm	1e-06	0.000292	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—AKT1—peripheral nervous system neoplasm	9.56e-07	0.000278	CbGpPWpGaD
Etodolac—PTGS2—Disease—NRAS—peripheral nervous system neoplasm	9.29e-07	0.000271	CbGpPWpGaD
Etodolac—RXRA—Metabolism—AKT1—peripheral nervous system neoplasm	8.92e-07	0.00026	CbGpPWpGaD
Etodolac—PTGS2—Disease—MYC—peripheral nervous system neoplasm	8.66e-07	0.000252	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—AKT1—peripheral nervous system neoplasm	7.77e-07	0.000226	CbGpPWpGaD
Etodolac—PTGS2—Disease—HRAS—peripheral nervous system neoplasm	6.8e-07	0.000198	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—AKT1—peripheral nervous system neoplasm	6.33e-07	0.000184	CbGpPWpGaD
Etodolac—PTGS2—Disease—AKT1—peripheral nervous system neoplasm	6e-07	0.000175	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—AKT1—peripheral nervous system neoplasm	5.03e-07	0.000146	CbGpPWpGaD
Etodolac—ALB—Metabolism—AKT1—peripheral nervous system neoplasm	4.07e-07	0.000118	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	3.33e-07	9.7e-05	CbGpPWpGaD
